Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review

Jiayi Li1,2,3†, Xin Zhang1,2,3,4†, Zhuanzhuan Mu1,2,3,4, Di Sun1,2,3,4, Yuqing Sun1,2,3,4 and Yansong Lin1,2,3*  

1Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China, 2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China, 3State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China, 4Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Background: Patients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of progressive RAIR DTC treated with apatinib plus camrelizumab.

Case presentation: We reported a 43-year-old man diagnosed as DTC with metastases in the lungs, the 7th cervical vertebra, and malignant lymph nodes mainly in the mediastinum. While initially showing disease stabilization after giving the first-line multitargeted kinase inhibitor (MKI) therapy, the patient developed progressive disease and was enrolled into a combined therapy with both apatinib and camrelizumab on November 10, 2020. Upon the first 6 months, the combination therapy showed disease control in terms of both stable structural lesions and biochemical thyroglobulin (Tg) level. Six months later, a decrease over the targeted lesions was observed and a partial response (PR) according to RECIST 1.1 criteria was finally achieved upon 12 months’ assessment, followed by the decline in serum Tg level. The main adverse event was occasional diarrhea without treatment interruption.
Conclusion: We reported a case with RAIR DTC that benefited from combination immunotherapy, apatinib plus camrelizumab, after resistance from donafenib. We observed a gradually getting better efficacy and a mild and long duration of this combination therapy and hoped to provide a therapeutic choice for these patients.

KEYWORDS
radioactive iodine refractory, differentiated thyroid cancer, combination immunotherapy, multitargeted kinase inhibitors plus PD-1/PD-L1 inhibitors therapy, apatinib plus camrelizumab treatment

Introduction

The progression in differentiated thyroid cancer (DTC) can occur in up to approximately 20% after standard therapeutic approaches in the 10-year follow-up (1). After radioactive iodine (RAI) therapy, loss of the ability of iodine uptake can occur in two-thirds of these patients, which are called RAI-refractory, progressive differentiated thyroid cancer (RAIR-DTC) (2). Those with RAIR-DTC have a 10-year survival rate less than 10% survival, which greatly reduce clinical dilemma.

Currently, two multitargeted kinase inhibitors (MKI) sorafenib and lenvatinib have been approved for use in patients with progressive RAIR DTC by the National Medical Products Administration (NMPA) as the first-line systemic therapy based upon their promising antitumor activity (3). However, most RAIR-DTC patients developed resistance to MKIs over the following 1 to 2 years (4). In addition, drug-induced adverse effects were commonly seen with MKI treatment under standard doses, which may downgrade the patients’ quality of life and even lead to termination of MKI therapy (5). Cabozantinib is a recently approved therapy after first-line resistance (6). However, it is still a MKI therapy and could not be available in Chinese patients.

Immunotherapy PD-1/PD-L1 inhibitors have also achieved promising results in many tumor types such as melanoma and non-small cell lung cancer (7). A non-randomized, phase Ib trial KEYNOTE-028 estimated response of patients with RAIR-DTC to PD-1 and observed objective responses in a minority of patients (8). The influence of PD-1 treatment to RAIR-DTC must be substantiated in subsequent clinical trials. The combination of immunotherapy and MKIs is a topic of high interest in the treatment of advanced malignant tumors. Lenvatinib plus pembrolizumab showed more potent antitumor activity compared with either agent alone in mouse xenograft (9) and human studies (10), showing promising benefit in RAIR-DTC (11). Apatinib is a domestic MKI which showed rapid and significant efficacy in its phase II and phase III studies conducted in progressive RAIR-DTC (12), and apatinib plus camrelizumab is a combined therapy which has shown promising efficacy recently in patients with hepatocellular carcinoma or neuroendocrine carcinoma (13).

To our knowledge, apatinib combined with camrelizumab therapy has not been systematically reported in thyroid cancers. We presented here a case of progressive RAIR-DTC treated with apatinib plus camrelizumab (ClinicalTrials.gov Identifier: NCT04560127).

Case presentation

A 43-year-old man diagnosed with follicular thyroid cancer (FTC) with metastases in the lungs, the 7th cervical vertebra, and malignant lymph nodes mainly in the mediastinum and resistance to first-line MKI was given a combined therapy of antiangiogenic MKI apatinib and anti-PD-1 antibody camrelizumab in October 2020.

In 2015, the patient was diagnosed with DTC (Figures 1A, B) and received radical thyroidectomy and subsequent RAI therapy. Mutation analysis was performed, and results were positive for TERT, BRAF p.L597Q, and VEGF, while negative for RAS and BRAF p.VAL600. During the regular follow-up including cervical ultrasound and chest computed tomography (CT) scanning accompanied by TSH suppression therapy, recurrences were found in cervical lymph nodes, mediastinal lymph nodes, lungs, and the 7th cervical vertebra in 2017. Therefore, he received cervical lymph node dissection and several subsequent RAI therapies. However, his pulmonary lesions did not take iodine revealed by whole-body iodine scan after last RAI therapy in October 2019 (Figure 1C). Thus, he was identified as RAIR after receiving several surgeries and RAI therapies with a cumulative dose of 670 mCi. He was then given a first-line MKI in October 2019. While initially showing disease stabilization after giving the first-line MKI, the patient developed...
progressive disease (PD) and terminated the first-line MKI therapy on September 10, 2020.

Followed by a 4-week discontinuation, the patient was enrolled into an exploratory phase II clinical trial combining antiangiogenic MKI apatinib and anti-PD-1 antibody camrelizumab in November 2020. The therapeutic schedule was given by 250 mg apatinib orally once daily and 200 mg camrelizumab intravenously once every 2 weeks in a 4-week cycle. The patient was evaluated every cycle in the first 2 cycles and every 2 cycles thereafter. During the first 6 months’ assessment, the combination therapy initially showed disease control in terms of both stable structural lesions and biochemical thyroglobulin (Tg) level (Figure 2). Six months later from April 2021, the targeted and non-targeted lesions began to shrink rapidly followed by a rapid decrease in serum Tg, and a partial response (PR) according to RECIST 1.1 criteria was finally achieved upon 12 months’ assessment in October 2021 (targeted lesions: 4.7 to 2.9 cm) (Figures 2B, C). Along with this process, the biochemical Tg level also decreased from 22,481 ng/ml (October 2020) to 5,351 ng/ml (October 2021) (Figure 2D).

During this process, the main adverse event was occasional diarrhea without treatment interruption. The patient was in the state of PR at the last assessment and will be followed up in the future.

Discussion

We presented here a case of RAIR DTC with disease progression that responded to apatinib plus camrelizumab after resistance to an antiangiogenic drug. To our knowledge, we believed this was the first case of RAIR DTC with disease progression treated with apatinib plus camrelizumab. The patient showed a durable and safe response of nearly 1 year.

In our case, the patient with RAIR DTC got resistant to the first MKI donafenib. There were no public-approved treatments for RAIR DTC patients who became resistant to MKI in China. A number of previous clinical studies have explored the use of camrelizumab combined with apatinib for hepatocellular carcinoma, NSCLC, SCLC, cervical cancer, breast cancer, osteosarcoma, esophageal squamous cell carcinoma, colorectal carcinoma, gestational trophoblastic neoplasia, biliary tract cancer, and gastric and esophageal gastric junction cancer and showed promising results (14–25) (Table 1). Another combination therapy of immunotherapy PD-1 inhibitors and MKIs, lenvatinib plus pembrolizumab, showed disease control in thyroid cancer. Luongo et al. (26) showed that patients with paucicellular variant anaplastic thyroid cancer reached PR 5 months after giving lenvatinib plus pembrolizumab and PR persisted over 18 months. Dierks et al. (27) and Iyer et al. (28) showed that disease control happened in over half of patients with thyroid cancer after lenvatinib plus pembrolizumab therapy (Table 2). The efficacy of these studies was consistent with our research. The mechanism may be related to that use of MKI could normalize the abnormal tumor vasculature, thus increasing the infiltration of immune effector cells like CD4+ and CD8+ T cells into tumors (30–32). Preclinical experiments also found that apatinib could enhance the efficacy of PD-1/PD-L1 blockade through alleviating hypoxia, increasing
the infiltration of CD8+ T cells, and reducing tumor-associated macrophage recruitment and TGFβ amounts in both tumor and serum (33). The selection of dosing is also a question needed to be resolved. Previous fundamental studies observed a more favorable microenvironment for immunotherapy in low-dose apatinib instead of high-dose treatment (33). Therefore, the dose of our case is 250 mg apatinib in combination with 200 mg camrelizumab, which was consistent with previous studies (Table 1).

The response pattern of this combined therapy featured as initial stabilization and delayed tumor reduction was quite different from the current effect of mono-MKI therapy, which may suggest the difference between our combined effect and monotherapy. As we previously mentioned, patients always showed rapid response to antiangiogenic drugs but progressed eventually. Previous studies found that in apatinib monotherapy, the serum Tg level decreased as early as 2 weeks (34), the median time to objective response was 1.9 months (29), and an expected time to progression was between 11 and 18 months (33, 35). Meanwhile, the response to immunotherapy seems to be more durable. A study found that time to response for patients with DTC after PD-1 inhibitor therapy who reached PR was 4 to 5 months (11). For our patient, time to PR was much longer than previous research of apatinib monotherapy. In addition, we did not find the patient who showed the same response pattern in apatinib monotherapy. Therefore, the first 6-month response in this patient may suggest the effect of a low-dose MKI to some extent, while the subsequent response may suggest the effect of immunotherapy. The long duration indicated a mild and lasting therapeutic effect of low-dose apatinib combined with camrelizumab in thyroid cancer.

During this process, the main adverse event was occasional diarrhea without treatment interruption. Adverse events including hand–foot syndrome, hypertension, and proteinuria are commonly observed in apatinib therapy but did not appear in this patient (36), which may suggest the safety of a low-dose schedule. The reactive cutaneous capillary endothelial proliferation was a common adverse event in camrelizumab therapy (37). There is a hypothesis that apatinib, a kind of antiangiogenic drug, would inhibit the proliferation of endothelial cells and thus would present a counteracting effect against adverse effects of camrelizumab. Compared with camrelizumab monotherapy, the skin capillary hyperplasia symptoms in combined therapy were lower than before (Table 1).

The change in serum Tg level in our case also suggested the potential prediction value of serum Tg on target and immunotherapy. The correlation between ps-Tg and therapeutic response was proposed in 2015 American Thyroid Association guidelines, and the relationship between Tg and apatinib plus camrelizumab therapy needed to be confirmed (2). Therefore, our results indicated the value of Tg in observing response to target therapy.
TABLE 1 Clinical studies for lenvatinib combined with pembrolizumab for the treatment of thyroid cancer.

| Author            | Disease                          | Interventions                                                                 | Efficacy                                                                 | Adverse event                                                                 |
|-------------------|----------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Jianming Xu et al. (15) | Advanced hepatocellular carcinoma | Camrelizumab 200 mg (for bodyweight ≥50 kg) or 3 mg/kg (for bodyweight <50 kg) every 2 weeks plus apatinib 250 mg daily | First-line ORR 34.3%, median PFS 5.7 months, 12-month survival rate 74.7%; second line ORR 22.5%, median PFS 5.5 months, 12-month survival rate 68.2% | Grade ≥3 AEs 77.4%, most hypertension 34.2%, serious AEs 28.9%, treatment-related deaths 1.1% |
| Kuimin Mei et al. (14) | Advanced primary liver cancer   | Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (125, 250, 375, or 500 mg; once per day) | ORR 10.7%, median PFS 3.7 months, median OS 13.2 months | Grade ≥3 AEs 92.9% |
| Shengxiang Ren et al. (16) | Advanced non-squamous NSCLC     | Camrelizumab 200 mg every 2 weeks plus apatinib 250 mg once daily             | ORR 40.0%, disease control rate 92.0%, median PFS 9.6 months              | Grade ≥3 AEs 80% |
| Yun Fan et al. (17) | Extensive-stage SCLC            | Camrelizumab 200 mg every 2 weeks plus apatinib 375 mg once daily             | ORR 34.0%, median PFS 3.6 months, median OS 8.4 months                   | Grade ≥3 AEs 72.9%, discontinued 8.5% |
| Chunyan Lan et al. (18) | Advanced cervical cancer       | Camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day            | ORR 55.6%, median PFS 8.8 months                                         | Grade ≥3 AEs 71.1%, hypertension 24.4%, anemia 20.0%, fatigue 15.6% |
| Joqiong Liu et al. (19) | Advanced triple-negative breast cancer | Camrelizumab every 2 weeks with apatinib 250 mg at either continuous dosing (di-d14) or intermittent dosing (d1-d7) | Continuous cohort: ORR 43.3%, median PFS 3.7 months; intermittent cohort ORR 0, median PFS 1.9 months | Grade ≥3 AEs 46.7% |
| Lu Xie et al. (20) | Advanced osteosarcoma          | Apatinib 500 mg once daily plus camrelizumab 200 mg by every 2 weeks          | ORR 20.9%, Median PFS 6.2 months, median OS 11.3 months                  | Grade ≥3 AEs 69.8% |
| Xiangrui Meng et al. (21) | Advanced esophageal squamous cell carcinoma | Camrelizumab 200 mg every 2 weeks plus apatinib 250 mg once daily            | ORR 34.6%, disease control 78.8%, median PFS 6.8 months, median OS 15.8 months | Grade ≥3 AEs 44%, most increased aspartate aminotransferase 19%, increased gamma-glutamyl transferase 19%, increased alanine aminotransferase 10% |
| Chao Ren et al. (22) | Metastatic colorectal cancer    | Camrelizumab 200 mg every 2 weeks and apatinib 250–375 mg once daily         | ORR 0%, disease control rate 22.2%, median PFS 1.83 months, median OS 7.80 months | Grade 3 AEs 90%, most hypertension 30% |
| Hongyan Cheng et al. (23) | Chemorefractory or relapsed gestational trophoblastic neoplasia | Camrelizumab 200 mg every 2 weeks plus apatinib 250 mg once per day            | ORR 55%, complete response 50%                                           | Grade 3 AEs 60% |
| Dongxi Wang et al. (24) | Advanced biliary tract cancer  | Apatinib at 250 mg per a day and camrelizumab intravenously at 200 mg every three weeks | PR 19%, disease control rate 71.4%, median PFS 4.4 months, median OS 13.1 months | Grade ≥3 AEs 63.6% |
| Jianming Xu et al. (25) | Advanced hepatocellular carcinoma, gastric, or esophageal junction cancer | Camrelizumab 200 mg every 2 weeks and apatinib 125–500 mg once daily           | PR 50.0%, ORR 30.8%                                                      | Grade ≥3 AEs 60.6% |

ORR, objective response rate; PFS, progression-free survival; OS, overall survival; AEs, adverse effects; PR, partial response; SD, stable disease; PD, progressive disease.

TABLE 2 Clinical studies for camrelizumab combined with apatinib for the treatment of other diseases.

| Author            | Disease                          | Interventions                                                                 | Efficacy                                                                 | Adverse event                                                                 |
|-------------------|----------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Christine Dietz et al. (27) | 6 patients with metastatic ATC and 2 patients with PDTC | Lenvatinib 14–24 mg daily combined with pembrolizumab 200 mg every 3 weeks | Overall PR 6/8, ATCs ORR 66%, median PFS 17.75 months, median OS 18.5 months | Grade ≥3 AEs 50% |
| Cristina Luongo et al. (26) | One patient with paucicellular variant ATC | Lenvatinib (24 mg daily) in combination with pembrolizumab (200 mg every 21 days) | PR achieved after 5 months, PR of lung metastasis persisted over 18 months | Grade 3 diarrhea, vomiting, and weight loss |
| Priyanka C flyer et al. (28) | 12 patients with ATC             | 6 patients: pembrolizumab plus dabrafencib and trametinib; 5 patients: pembrolizumab plus lenvatinib; 1 patient: pembrolizumab plus trametinib | PR 5/12 (42%), SD 4/12 (33%), PD 3/12 (25%), median OS 6.93 months, median PFS 2.96 months | Fatigue, anemia, hypertension |

ATC, anaplastic thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; AEs, adverse effects; PR, partial response; SD, stable disease; PD, progressive disease.
Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The study was approved by the Ethics Committee of Peking Union Medical College Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

JL and XZ: conceptualization; data curation; formal analysis; investigation; methodology; software; visualization; writing—original draft. ZM, DS, and YS: supervision; validation; visualization; writing—review and editing. YL: conceptualization; funding acquisition; methodology; project administration; resources; software; supervision; validation; visualization; writing—review and editing. All authors contributed to the article and approved the submitted version.

Funding

This study was funded by the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2020-12M-2-003), the CSCO-Hengrui Research Foundation (No. Y-HR2018-143, Y-HR2018-144), the National Natural Science Foundation of China (grant 81771875), and the Project on Inter-Governmental International Scientific and Technological Innovation Cooperation in the National Key Projects of Research and Development Plan (grant 2019YFE0106400). In addition, apatinib and camrelizumab were provided by Jiangsu Hengrui Pharmaceuticals Co Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoa F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. *Lancet Diabetes Endocrinol* (2014) 2:356–8. doi: 10.1016/s2213-8587(13)70215-8
2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* (2016) 26:1–133. doi: 10.1089/thy.2015.0020
3. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Batholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *Lancet* (2014) 384:319–28. doi: 10.1016/s0140-6736(14)60421-9
4. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. *N Engl J Med* (2015) 372:621–30. doi: 10.1056/NEJMoa1406470
5. Pitoa F, Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. *Drug Des Devel Ther* (2016) 10:1119–31. doi: 10.2147/dddt.s82972
6. Wang E, Karedan T, Perez CA. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. *Anticancer Drugs* (2015) 26:689–97. doi: 10.1097/cad.0000000000000247
7. Ancker OV, Krüger M, Wehland M, Infanger M, Grimm D. Multikinase inhibitor treatment in thyroid cancer. *Int J Mol Sci* (2019) 21. doi: 10.3390/ijms2010310
8. Laursen R, Wehland M, Kopp S, Pietsch J, Infanger M, Grosse J, et al. Effects and role of multikinase inhibitors in thyroid cancer. *Curr Pharm Des* (2016) 22:5915–26. doi: 10.2174/1381612822666160614084943
9. Brose MS, Robinson B, Sherman SJ, Krajewska J, Lin OC, Vaisman F, et al. Gabzeitumizib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* (2021) 22:1126–38. doi: 10.1016/s1470-2045(21)00332-6
10. Alsaab HO, Sau S, Alhrami R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signalling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. *Front Pharmacol* (2017) 8:561. doi: 10.3389/fphar.2017.00561
11. Mehnter JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. *BMC Cancer* (2019) 19:196. doi: 10.1186/s12885-019-5380-3
12. Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepat-6 hepatocellular carcinoma model. Cancer Sci (2018) 109:3993–4002. doi: 10.1111/cas.13806

13. Mo DC, Luo PH, Huang SX, Wang HI, Huang JF. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. Int Immunopharmacol (2021) 91:107281. doi: 10.1016/j.intimp.2020.107281

14. Mei K, Qin S, Chen Z, Liu Y, Wang L, Zou J. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase IIb trial. J Immunother Cancer (2021) 9. doi: 10.1136/jitc-2020-002191

15. Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (CAP 02): A nonrandomized, open-label, phase II trial. Clin Cancer Res (2021) 27:1003–11. doi: 10.1158/1078-0432.ccr-20-2571

16. Ren S, He J, Fang Y, Chen G, Ma Z, Chen J, et al. Camrelizumab plus apatinib in treatment-naïve patients with advanced nonquamous NSCLC. A multicenter, open-label, single-arm, phase 2 trial. JTO Clin Rep (2022) 3:100312. doi: 10.1016/j.jtocrr.2022.100312

17. Fan Y, Zhao J, Wang Q, Huang D, Li X, Chen J, et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): A multicenter, two-stage, phase 2 trial. J Thorac Oncol (2021) 16:299–309. doi: 10.1016/j.jtho.2020.10.002

18. Lan C, Shen J, Wang Y, Li J, Liu Z, He M, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial. J Clin Oncol (2020) 38:4095–106. doi: 10.1200/jco.20.01920

19. Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer (2020) 8. doi: 10.1186/s40425-020-000696

20. Xie L, Xu J, Sun X, Guo W, Gu J, Liu K, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm phase 2 trial. JTO Clin Rep (2022) doi:10.1016/j.jtocrr.2022.100312

21. Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, et al. Camrelizumab plus apatinib as second-line treatment for advanced esophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol (2022) 7:245–53. doi: 10.1016/s2542-1715(21)00378-2

22. Ren C, Mai ZJ, Jin Y, He MM, Wang ZQ, Luo HY, et al. Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. Am J Cancer Res (2020) -10.2946–54.

23. Cheng H, Zong L, Kong Y, Wang X, Gu Y, Cang W, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol (2021) 22:1609–17. doi: 10.1016/s1470-2045(21)00460-5

24. Wang D, Yang X, Long J, Lin J, Mao J, Xie F, et al. The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: A prospective clinical study. Front Oncol (2021) 11:646979. doi: 10.3389/fonc.2021.646979

25. Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study. Clin Cancer Res (2019) 25:515–23. doi: 10.1158/1078-0432.ccr-18-2484

26. Luongo C, Porcelli T, Sessa F, De Stefano MA, Scavuzzo F, Damiano V, et al. Combination of lenvatinib and pembrolizumab as salvage treatment for pseudocarcinomatous variant of anaplastic thyroid cancer: A case report. Curr Oncol (2021) 28:5401–7. doi: 10.3399/curomc.2021.2806050

27. Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid (2020) 31:1076–85. doi: 10.1089/ thy.2020.0322

28. Iyer PC, Dadu R, Gule-Monroe M, BasuAD, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer (2018) 6:68. doi: 10.1186/ s40425-018-0378-y

29. Lin Y, Qin S, Li Z, Yang H, Fu W, Li S, et al. Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: The REALITY randomized clinical trial. JAMA Oncol (2022) 8:422–50. doi: 10.1001/jamaoncol.2021.6268

30. Fukumura D, Kloepper J, Amooogar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol (2018) 15:325–40. doi: 10.1038/nrc2018.29

31. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U.S.A. (2012) 109:17561–6. doi: 10.1073/pnas.1215397109

32. Schmittnaegel M, Rigamonti N, Kadoglu E, Cassarà A, Wyser Rimili C, Kiulainen A, et al. Dual angiotatin-2 and VEGF inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med (2017) 9. doi: 10.1126/scitranslmed.aak9670

33. Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol Res (2019) 7:630–43. doi: 10.1158/2326-6066.cir-17-0640

34. Lin Y, Wang C, Guo W, Cui R, Liang J, et al. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget (2017) 8:42252–61. doi: 10.18632/oncotarget.15036

35. Brose MS, Schlumberger M, Jeffers M, Kappeler C, Meinhardt G, Peña CEA. Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: Subanalysis of the sorafenib phase III DECISION trial. Clin Cancer Res (2019) 25:3730–80. doi: 10.1158/1078-0432.ccr-18-3439

36. Shao F, Zhang H, Yang X, Luo X, Liu J. Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review. Neoplasma (2020) 67:715–23. doi: 10.4149/neu_2020_1908017001

37. Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen Z, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol (2020) 13:47. doi: 10.1186/s13045-020-00886-2